Cited 51 times in

Changes in bone mineral density and bone turnover markers during treatment with teriparatide in pregnancy- and lactation-associated osteoporosis

DC Field Value Language
dc.contributor.author이수진-
dc.contributor.author이유미-
dc.contributor.author홍남기-
dc.date.accessioned2018-08-28T17:22:44Z-
dc.date.available2018-08-28T17:22:44Z-
dc.date.issued2018-
dc.identifier.issn0300-0664-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/162540-
dc.description.abstractCONTEXT: Teriparatide (TPTD) therapy has been proposed as a potential treatment strategy in severe cases of pregnancy- and lactation-associated osteoporosis (PLO) characterized by the occurrence of fragility fractures in the third trimester or early postpartum. OBJECTIVE: To investigate the changes in bone mineral density (BMD) and bone turnover markers in patients with PLO with and without TPTD treatment. DESIGN: Retrospective cohort study. PATIENTS: Thirty-two patients with PLO who presented with multiple vertebral fractures to a tertiary institution between 2007 and 2015 were included. MEASUREMENTS: Changes in BMD at the lumbar spine (LSBMD) and proximal femur after 12 months of daily subcutaneous injections of 20 mug TPTD (n = 27) were assessed. Subjects who rejected the TPTD treatment were used as controls (n = 5). RESULTS: LSBMD increased in both subjects treated with TPTD and controls, with greater increases in the TPTD group (15.5 +/- 6.6% vs 7.5 +/- 7.1%, P = .020) after adjustment for age and baseline LSBMD. During follow-up, serum levels of osteocalcin (OCN) and C-telopeptide of type I collagen (CTX) increased significantly in the TPTD group. In multivariate linear regression models, TPTD treatment (adjusted beta = 7.92, P = .032) and younger age (adjusted beta = 1.06, P = .046), but not baseline LSBMD, body mass index, serum OCN level and CTX level, were independently associated with greater increases in LSBMD. CONCLUSIONS: In patients with PLO, LSBMD at 12 months increased in both the TPTD-treated and control groups. TPTD treatment and younger age were associated with greater increases in LSMBD irrespective of baseline LSBMD.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherBlackwell Publishing-
dc.relation.isPartOfCLINICAL ENDOCRINOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.titleChanges in bone mineral density and bone turnover markers during treatment with teriparatide in pregnancy- and lactation-associated osteoporosis-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine-
dc.contributor.departmentDept. of Internal Medicine-
dc.contributor.googleauthorNamki Hong-
dc.contributor.googleauthorJo Eun Kim-
dc.contributor.googleauthorSu Jin Lee-
dc.contributor.googleauthorSe Hwa Kim-
dc.contributor.googleauthorYumie Rhee-
dc.identifier.doi10.1111/cen.13557-
dc.contributor.localIdA02894-
dc.contributor.localIdA03012-
dc.contributor.localIdA04388-
dc.relation.journalcodeJ00571-
dc.identifier.eissn1365-2265-
dc.identifier.pmid29389010-
dc.identifier.urlhttps://onlinelibrary.wiley.com/doi/abs/10.1111/cen.13557-
dc.subject.keywordidiopathic osteoporosis-
dc.subject.keywordpregnancy-associated osteoporosis-
dc.subject.keywordpremenopausal women-
dc.subject.keywordrecombinant human parathyroid hormone (1-34)-
dc.subject.keywordvertebral fracture-
dc.contributor.alternativeNameLee, Su Jin-
dc.contributor.alternativeNameRhee, Yumie-
dc.contributor.alternativeNameHong, Nam Ki-
dc.contributor.affiliatedAuthorLee, Su Jin-
dc.contributor.affiliatedAuthorRhee, Yumie-
dc.contributor.affiliatedAuthorHong, Namki-
dc.citation.volume88-
dc.citation.number5-
dc.citation.startPage652-
dc.citation.endPage658-
dc.identifier.bibliographicCitationCLINICAL ENDOCRINOLOGY, Vol.88(5) : 652-658, 2018-
dc.identifier.rimsid60121-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.